Research Shows CBD Can Treat GVHD

November 27, 2019 16:00:40

Graft versus host disease (GVHD) is a complication that occurs when donor bone marrow or stem cells attack the recipient. The donor cells see the host cells as foreign and attack them. It can range from mild to life-threatening in severity. Last week, Kalytera Therapeutics Inc. announced their research, reported in two peer-reviewed articles published in Blood, a medical journal published by the American Society of Hematology, about CBD’s ability to help manage GVHD.

One article explored the case of a 35-year-old patient who, after a bone marrow transplant, developed a particularly aggressive skin variant of GVHD that’s difficult to manage and carries a poor prognosis. He was treated with a cannabinoid solution and within three months, there was a definite improvement, so much so that he was discontinued from…


About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.